Site icon Market Globalist

Why Theravance Biopharma Inc (TBPH) stock facing negativity?

MITO Stock

MITO Stock

Theravance Biopharma Inc (TBPH) stock price declined on Friday, March 12, 2021, and even in the after-hours trading session, the negative trend continues.TBPH lost 12.69% in the extended-hours trading session on Friday. Still, there is no recent news to validate their share loss.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.  

Recent Business Activities

On February 23, 2021, TBPH announced its financial results for the fourth quarter and full-year 2020 ended on December 31, 2020.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Read More

Fourth Quarter Financial Highlights  

Full-year Financial Highlights

Recent events/Participation

TBPH participated in a pre-recorded Fireside Chat (investors conference) at the H.C. Wainwright Global Life Sciences Conference on Tuesday, March 9.

About TBPH

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development, and commercialization of organ-selective medicines. TBPH‎’s purpose is to create transformational medicines to improve the lives of patients suffering from serious illnesses. Our research is focused on the areas of inflammation and immunology.

TBPHhas some important products such as FDA-approved YUPELRI which is used for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.  

Rick E Winningham is the current CEO and Chairman of the company. He has more than 30 years of experience in biopharmaceuticals and has worked at senior management positions in different companies, around the globe.  He is graduated from Texas Christian University with an M.B.A degree and also holds a B.S. degree from Southern Illinois University.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Exit mobile version